Kühne Legacy, Boston Scientific Insider Buys, and AI Market Shifts
Analysis of Klaus Michael Kühne's estate strategy, Boston Scientific's insider buying amid product saturation, and the intensifying US-China tech competition in AI and robotics. Includes actionable insights on medtech valuation and macroeconomic risks.